Pancreatic ductal adenocarcinoma (PDAC) is characterized by its intricate biology governed by spatiotemporal dynamics in the expression and function of specific proteins. Here, DKK3 is identified as a dynamic player with a dual role in PDAC. Using the KRAS G12D ‐driven mouse model with homozygous (DDKC) and heterozygous (DKC) DKK3 knockout, its stage and compartment‐specific functions are investigated. Knockout mice exhibited shorter lifespans with a higher incidence of high‐grade, desmoplastic, and metastatic cancers. DKK3‐deficient acini exhibited a marked increase in acinar‐to‐ductal metaplasia, with increased MAPK signaling and induction of the downstream effector Fos . During the progression of mouse and human PDAC, DKK3 expression shifted from epithelial dysplastic cells to cancer‐associated fibroblasts (CAFs). At the endpoint, DKK3‐expressing CAFs emerged as crucial contributors to tumor aggressiveness and fibrosis. Orthotopic transplantations confirm a stromal role, particularly in DDKC tumors, while mechanistic studies demonstrate that DKK3 activates IL6‐JAK‐STAT3 signaling and pro‐migratory/mesenchymal programs that are reversed by pharmacologic STAT3 inhibition in DDKC cells. Concordantly, DKK3 expression correlates with IL6‐JAK‐STAT3 gene signatures in human PDAC datasets. Together, these findings underscore the intricate and context‐sensitive role of DKK3, delaying oncogenesis during early stages while paradoxically promoting tumor progression in later stages, suggesting that therapeutic targeting strategies should be approached with caution.
The tumor microenvironment (TME) actively contributes to pancreatic ductal adenocarcinoma (PDAC) pathogenesis through dynamic bidirectional tumor–stroma interactions. In this study, we demonstrated that ATM-deficient tumor epithelium reprograms the TME in a genotype-specific manner to enhance cancer aggressiveness. In genetically engineered mouse models, pancreatic stellate cell and cancer-associated fibroblast (CAF) coculture systems, single-nucleus multiomics, and human PDAC models, tumoral loss of ATM serine/threonine kinase drove CAFs toward αSMA+ myofibroblastic (myCAF) differentiation, independently of p53 status. The myCAFs, in turn, promoted cancer aggressiveness and chemoresistance. Mechanistically, ATM deficiency increased reactive oxygen species and contractility signaling, enhancing TGFβ1 secretion. Pharmacologic TGFβ inhibition reversed myCAF differentiation, sensitized tumors to chemotherapy, and impaired tumor progression in both murine and human ATM-null models. These findings reveal that ATM-deficient tumors shape a cancer-promoting niche via TGFβ signaling and identify dual targeting of intrinsic and extrinsic vulnerabilities as a promising precision oncology strategy. Significance: TGF-β-driven myofibroblastic stromal differentiation in ATM-deficient pancreatic cancer generates a genotype-specific tumor microenvironment, providing a targetable axis and highlighting the need to integrate epithelial genotype and stromal context in pancreatic cancer therapy.
ROS measurements, cytoskeletal marker expression, migration assays, and PSC differentiation analyses following genetic and pharmacologic perturbation of ROS and cytoskeletal pathways in ATM-deficient tumor models.
PSC-induced chemotherapy resistance and in vitro and ex vivo assays assessing apoptosis, invasion, wound closure, and drug response after perturbation of tumor–CAF signaling.